June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Ocular surface mast cells delay regression of pathological corneal blood vessels
Author Affiliations & Notes
  • WonKyung Cho
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Elsayed Elbasiony
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Yilin Guan
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Aastha Singh
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Sharad Mittal
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Sunil Chauhan
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   WonKyung Cho None; Elsayed Elbasiony None; Yilin Guan None; Aastha Singh None; Sharad Mittal None; Sunil Chauhan None
  • Footnotes
    Support  NEI R01EY029727
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 422. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      WonKyung Cho, Elsayed Elbasiony, Yilin Guan, Aastha Singh, Sharad Mittal, Sunil Chauhan; Ocular surface mast cells delay regression of pathological corneal blood vessels. Invest. Ophthalmol. Vis. Sci. 2022;63(7):422.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Corneal angiogenesis, induced by various ocular insults, compromises corneal transparency. Our previous studies have shown that activation of ocular surface mast cells directly promote the development of new blood vessels. Here we investigated whether mast cells contribute to the stability of inflammatory blood vessels and impede vessel regression.

Methods : Neovascularization was induced by placing a single figure-8 intrastromal suture in the cornea using 11-0 nylon. On day 9, the suture was removed upon establishment of mature blood vessels. Corneas were harvested and stained with avidin+ (mast cells) and CD31+ (vascular endothelial cells) for immunohistochemistry (IHC) analysis. Real-time vessel regression was followed by capturing slit-lamp pictures. To investigate the direct effect of mast cells on vessel regression, suture was placed in mast cell deficient cKitw-sh and their wildtype (WT) C57BL/6 controls. To evaluate the effect of pharmacological blockade of mast cells on the reversion of mature blood vessels, corneas were treated one day prior to suture removal with mast cell inhibitor, cromolyn (2% in PBS). Slit lamp images were analyzed using ImageJ software. Corneas were harvested on day of suture removal and 2 days post-suture removal and expression of angiogenic factor, VEGF, was quantified to assess vessel regression at the molecular level.

Results : IHC analysis demonstrated an abundance of mast cells surrounding the new corneal blood vessels on day 9 post-suture. By 48 hours following suture removal, a significant 51.3% (± 0.67%) regression of blood vessels were observed in cKitw-sh mice, compared to 11.5% (± 2.15%) regression in WT controls (p=0.002). Established vessels completely regressed in cKitw-sh mice by day 7 post-suture removal. Moreover, cromolyn treatment promoted faster regression of inflammatory blood vessels, as demonstrated by complete regression of pathological vessels by 24 hours post-suture removal, compared to PBS treatment resulting in no significant change in the inflammatory vessels. Furthermore, molecular analysis of vessel regression showed a 59% lower expression of VEGF in the cromolyn-treated corneas, relative to PBS-treated groups (p=0.03).

Conclusions : Our data demonstrate that deficiency of ocular surface mast cell function results in faster regression of pathologic corneal blood vessels, suggesting mast cells promote the stability of inflammatory vessels.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×